CTOs on the Move

CARsgen

www.carsgen.com

 
CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.carsgen.com
  • 6575 West Loop South Suite 455
    Bellaire, TX USA 77401
  • Phone: 346.293.9392

Executives

Name Title Contact Details

Similar Companies

Fremont Analytical Inc

Fremont Analytical Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Asher Bio

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases.

Treasure Coast Radiation Oncology, Pa

Treasure Coast Radiation Oncology, Pa is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ArcherDX

ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types.

Elucida Oncology

Elucida Oncology, Inc., is a clinical development stage company based on proprietary ultra-small C-Dot technology to find, see and treat an array of solid tumor cancers. Developed and clinically translated by Memorial Sloan-Kettering Cancer Center and Cornell University, C-Dots have published human safety and tumor-specific clinical data. Elucida Oncology is currently progressing through a broad clinical trial program while continuing to drive a future portfolio through ongoing innovation.